14 October 2009
Evident clinical response to erlotinib as third-line treatment in EGFR FISH (+) male smoker patient with adenocarcinoma of lung
Pawel Krawczyk, Wojciech Remiszewski, Elżbieta Czekajska-Chehab, Beata Gryglicka, Edward Warda, Maciej Pelak, Kamila Wojas-Krawczyk, Olga Jankowska, Tomasz Mazurkiewicz, Janusz MilanowskiAm J Case Rep 2009; 10:166-171 :: ID: 878220
Abstract
Background: Bronchoalveolar carcinoma (BAC) is a “minimally invasive” form of adenocarcinoma, which spreads along the intraalveolar septum and is poorly associated with cigarette smoking. The EGFR tyrosine kinase inhibitors (TKIs), e.g. erlotinib or gefi tinib, have proven effective in some patients with advanced non-small cell lung cancer previously treated and progressive on chemotherapy. Female, never-smokers or histology of adenocarcinoma or BAC are uncertain favourable factors for positive clinical outcome in EGFR TKIs therapy. However, increased EGFR gene copy number without EGFR protein expression has been shown in several studies to be a good predictive marker for this treatment.
Case Report: In the present paper, we reported a rare case of adenocarcinoma with BAC pattern evidently responding to erlotinib in the absence of EGFR protein expression on cancer cells. However, increased EGFR gene copy number in cancer cells was detected by fl uorescent in situ hybridisation (FISH). Unusually, for 8 months we have observed partial remission in smoking male patient with multiple distant metastases after the failure of fi rst- and second-line chemotherapy. The complete regression of multiple cancer micronodules in the lung and brain metastases, partial reduction of metastases in mediastinal lymph nodes and liver as well as stabilisation of bone metastases were noted.
Conclusions: Tyrosine kinase inhibitors may play an important role in BAC treatment especially with increased EGFR gene copy number in tumour cells, even in smokers and in the absence of EGFR protein expression.
Keywords: lung adenocarcinoma, erlotinib, clinical response
In Press
06 Mar 2024 : Case report
Successful Healing of Periapical Pathology with Partial Pulpotomy in a Mature Permanent Molar: A Case ReportAm J Case Rep In Press; DOI: 10.12659/AJCR.942937
12 Mar 2024 : Case report
Successful Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus with Celecoxib: A Promising Therapeu...Am J Case Rep In Press; DOI: 10.12659/AJCR.943244
13 Mar 2024 : Case report
Recurrent Marginal Zone Lymphoma with Bone Marrow Involvement Detected by ¹⁸F-FDG PET/CT and Biopsy: A Diag...Am J Case Rep In Press; DOI: 10.12659/AJCR.943275
13 Mar 2024 : Case report
Unveiling the Temporal Aspect of MRI Tattoo Reactions: A Prospective Evaluation of a Newly-Acquired Tattoo ...Am J Case Rep In Press; DOI: 10.12659/AJCR.943411
Most Viewed Current Articles
07 Mar 2024 : Case report
Neurocysticercosis Presenting as Migraine in the United StatesDOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
10 Jan 2022 : Case report
A Report on the First 7 Sequential Patients Treated Within the C-Reactive Protein Apheresis in COVID (CACOV...DOI :10.12659/AJCR.935263
Am J Case Rep 2022; 23:e935263
19 Jul 2022 : Case report
Atlantoaxial Subluxation Secondary to SARS-CoV-2 Infection: A Rare Orthopedic Complication from COVID-19DOI :10.12659/AJCR.936128
Am J Case Rep 2022; 23:e936128
23 Feb 2022 : Case report
Penile Necrosis Associated with Local Intravenous Injection of CocaineDOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250